Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04341129 · ClinicalTrials.gov registry record · Early Phase 1
Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)
A Early Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
NCT04341129 is a Early Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 50 participants.
The verdict
NCT04341129, a Early Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Standard breast MRI studies often have lengthy protocols that make them inherently expensive and time-consuming. Several studies of the use of abbreviated MRI protocols have shown that the shorter protocols have diagnostic accuracy comparable to that of the conventional full MRI protocol. There are also promising results of ultrafast DCE-MRI studies with shorter breast MRI protocols that provide not only morphologic but also valuable kinetic information about a lesion. The shorter imaging times achieved with the abbreviated and the ultrafast DCE-MRI protocols have the potential to increase efficiency and lower cost by decreasing time in the MRI suite, which in turn may make breast MRI accessible for population-based mass screening. The focus of the proposed research is the investigation of an abbreviated MRI protocol with ultrafast imaging using Dotarem® (Gadoterate Meglumine).
Interventions
- DRUG Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-07-13 |
| Est. Completion | 2023-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04341129
The ClinicalTrials.gov registry entry for NCT04341129 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine) is the first listed.
NCT04341129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04341129 about?
NCT04341129 is a clinical study titled "Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)". Standard breast MRI studies often have lengthy protocols that make them inherently expensive and time-consuming. Several studies of the use of abbreviated MRI protocols have shown that the shorter protocols have diagnostic accuracy comparable to that of the conventional full MRI protocol. There are ...
What is the current status of trial NCT04341129?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2020-07-13. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT04341129?
The interventions under investigation include: Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine) (DRUG).
Who is sponsoring clinical trial NCT04341129?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.